Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat
- 11 July 2005
- journal article
- Published by Elsevier BV in Neuropharmacology
- Vol. 49 (7), 996-1006
- https://doi.org/10.1016/j.neuropharm.2005.05.013
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophreniaNature Reviews Drug Discovery, 2004
- SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological ProfileNeuropsychopharmacology, 2003
- SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacologyEuropean Neuropsychopharmacology, 2002
- SLV313: A novel antipsychotic with additional antidepressant and anxiolytic-like actionsEuropean Neuropsychopharmacology, 2002
- DU 127090: a highly potent, atypical dopamine receptor ligand — a putative potent full spectrum antipsychotic with low EPS potentialEuropean Neuropsychopharmacology, 2000
- Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free SchizophrenicsNeuropsychopharmacology, 1997
- Phencyclidine-induced stereotyped behaviour and social isolation in ratsBehavioural Pharmacology, 1996
- Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brainNeuropharmacology, 1995
- Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsyJournal of Neural Transmission, 1991
- 8-Hydroxy-2-(dipropylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonistJournal of Medicinal Chemistry, 1981